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Performance status score: do patients and their oncologists agree?
SP Blagden*,1, SC Charman2, LD Sharples2, LRA Magee3 and D Gilligan1,3
1Department of Oncology, Box 193, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 2QQ, UK; 2MRC Biostatistics Unit, Institute of Public Health,
University Forvie Site, Robinson Way, Cambridge CB2 2SR, UK; 3Thoracic Oncology Unit, Papworth Hospital, Cambridge CB3 8RE, UK
Oncologists traditionally assess their patients’ ECOG performance status (PS), and few studies have evaluated the accuracy of these
assessments. In this study, 101 patients attending a rapid access clinic at Papworth Hospital with a diagnosis of lung cancer were asked
to assess their own ECOG PS score on a scale between 0 and 4. Patients’ scores were compared to the PS assessment of them made
by their oncologists. Of 98 patients with primary non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC), weighted k
statistics showed PS score agreement between patient and oncologist of 0.45. Both patient- and oncologist-assessed scores reflected
survival duration (in NSCLC and SCLC) as well as disease stage (in NSCLC), with oncologist-assessed scores being only marginally
more predictive of survival. There was no sex difference in patient assessment of PS scores, but oncologists scored female patients
more pessimistically than males. This study showed that, with few exceptions, patients and oncologists assessed PS scores similarly.
Although oncologists should continue to score PS objectively, it may benefit their clinical practice to involve their patients in these
assessments.
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Performance status
David A Karnofsky and colleagues described the first performance
status (PS) score in 1948 (Karnofsky et al, 1948). It was introduced
for assessing patients receiving nitrogen mustard chemotherapy
for primary lung carcinoma. Each patient was given a score on a
linear scale between 0 (dead) and 100 (normally active),
summarising their ability to perform daily activities, and the level
of assistance they required in order to do so. This scoring system
was subsequently used throughout oncology practice as a
numerical guide to patients’ general health. In 1960, the Eastern
Co-operative Oncology Group (ECOG) introduced a simpler
‘ECOG performance status’ scale, similar to the Karnofsky PS
(KPS) scale, with only five points. This is now termed the ECOG/
WHO score (Oken et al, 1982) having been expanded to comprise
of six points with the addition of PS 5 (Figure 1).
In a Medline Search using the terms ‘clinical trial and
Karnofsky/WHO or ECOG performance status’, 233 and 84 authors
used the ECOG and Karnofsky scores, respectively. Generally, the
two scores have been proven to be interchangeable (Taylor et al,
1999), although the ECOG is often preferred for its simplicity.
Interobserver agreement
A score is reliable if there is good concordance between observers,
and low rates of inter- and intraobserver variability. Studies of this
have been conflicting. When health professionals were asked to
assess the KPS of 75 cancer patients, Yates et al (1980) found
moderate agreement (correlation coefficient 0.69) between nurses
and social workers. Oncologists and psychiatrists or psychologists
had greater agreement with a correlation coefficient of 0.79. Roila
et al (1991) showed very high interobserver correlation between
two oncologists in assessing both the Karnofsky (coefficient 0.92)
and ECOG (coefficient 0.91) scores in 209 cancer patients, but
Sorenson et al (1993) showed only moderate overall nonchance
agreement among three oncologists who assessed the ECOG status
of 100 consecutive cancer patients seen in an outpatient clinic.
They had higher concordance in patients with good PS (ECOG PS
0-2) compared to those with poor PS (ECOG PS 3-4).
Correlation of performance status with other variables
Performance status scores are widely used in oncological practice
because they correlate with patient survival duration (Albain et al,
1991) and response to treatment (Sengelov et al, 2000), as well as
their quality of life (Finkelstein et al, 1988) and comorbidity (Firat
et al, 2002). This scoring system is therefore used to decide which
patients are physically suitable for treatment and/or entry into
clinical trials. Many lung cancer chemotherapy trials have a cutoff
of PS41 because patients with PS¼ 2 have been shown to have
particularly poor outcome in clinical trials after treatment
(Sweeney et al, 2001; Bunn, 2002).
A number of studies have measured the accuracy and reliability
of both Karnofsky and ECOG scores. To assess accuracy, Mor et al
(1984) demonstrated that the KPS of terminal cancer patients
correlated well with patient longevity. Buccheri et al (1996)
compared the KPS and ECOG PS in 536 patients with terminal
cancer and found that the ECOG test was better than the Karnofsky
score at predicting patient prognosis. Other studies have combined
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performance status with other variables (e.g. biological, prolif-
erative and serum markers) to give a more specific method of
scoring prognosis. There are now over 150 of such markers that
can be used to predict prognosis for patients with lung cancer
(Brundage et al, 2002), but PS is still the main (or only) prognostic
score commonly used.
To investigate whether PS correlated with survival, the
Edinburgh Lung Group (Capewell and Sudlow, 1990), conducted
a study in which the Karnofsky score of 651 newly registered
patients with lung cancer was assessed by physicians and then
correlated to the patients’ survival. In patients not treated
surgically, those with a KPS490 survived for a median 9.3
months, 6.2 months for an index of 80, 4.5 months for index 60– 70
and 1.2 months for an index of 50 or less.
Doctor –patient agreement
Performance scores are clearly very influential but are usually
assessed by clinicians rather than by patients themselves. This is in
contrast to quality of life scores, which are now subjectively
assessed by patients themselves, since it was shown that they were
more reliable & consistant at scoring their own quality of life than
their doctors (Slevin et al, 1988). Perhaps patients should routinely
be assessing not only their quality of life, but also their PS. This
would at least overcome the problem of interobserver variability.
A study to investigate this was performed by Ando et al (2001)
in Japan. In this study, 206 consecutive in-patients with stage III or
IV non-small-cell lung cancer (NSCLC) were asked to assess their
own PS and this was compared to an objective assessment by their
oncologists. Surprisingly, there was only moderate agreement
between the two groups, with patients being more pessimistic than
their physicians. The agreement was particularly poor between
female patients and their oncologists at 37.2% compared to 54%
between male patients and their oncologists. Overall, they found
that the oncologist-nominated PS correlated most closely to
observed survival data. They concluded that oncologists were
better at evaluating PS than the patients themselves.
The purpose of our study was to compare patient-assessed PS
with that recorded by the treating oncologist at the first clinic
appointment, before the patient was informed of their diagnosis.
We also aimed to evaluate the relationship between PS scores and
patient’s sex, their tumour stage and subsequent survival duration.
To measure ‘accuracy’, we wished to assess which PS (oncologist-
or patient-assessed) was more closely associated with survival.
MATERIALS AND METHODS
This was a prospective, nonrandomised, double-blinded, long-
itudinal study of the ECOG PS of patient seen consecutively,
attending a single institution (Papworth Hospital) with a
histological diagnosis of SCLC or NSCLC.
Between March 2000 and October 2001, 101 patients who
attended the Papworth two-stop oncology clinic with a suspected
diagnosis of lung cancer were prospectively entered into the study.
Before being seen by an oncologist, and before the diagnosis of
lung cancer was discussed, patients waiting in clinic were given an
information sheet about the study and asked if they would like to
take part. Those who agreed signed a consent form and were then
required to assess their own ECOG PS in a questionnaire by
placing a tick beside the statement that most accurately reflected
their functional ability over the preceding 2 weeks (Figure 1).
Following their clinic consultation, the oncologist recorded the
patient’s ECOG score using a similar questionnaire. Oncologists
participating in the study were requested to assess PS using their
usual clinical practice.
Once the patient and oncologist had completed the PS forms, the
research nurse took note of the patient’s age, sex, type and stage of
disease and the treatment plan. Both patient and oncologist were
blinded to the other’s PS assessment, and patients were asked not
to inform the oncologist of their selected score during the
consultation. The patient was then treated in the usual manner,
that is, with radiotherapy, chemotherapy, surgery or supportive
care according to the stage and type of their disease and their
clinician-assessed PS.
The research nurse monitored the outcome of patients that had
entered this study. Of those who died within 2 years of study
commencement, their date of death was recorded from the
Hospital Patient Administration System. This study met with
LREC approval.
STATISTICS
Agreement between patient and oncologist assigned-PS scores was
assessed using weighted k statistics and reported with 95%
confidence intervals (95% CI). Pearson’s w2 test was used to test
whether PS scores were associated with stage (NSCLC) or with sex.
Survival was calculated in months and days from date of trial entry
and initial PS assessment (usually the same as date of pathological
diagnosis) to the date of death, or 20 June 2002 if alive. Actuarial
survival was estimated using Kaplan–Meier methods and reported
as median (interquartile range (IQR)) or cumulative survival (95%
CI). Between-group comparisons were made using the log-rank
test. Univariate Cox’s regression was used to evaluate which score
(patient- or oncologist-assessed) was a better fit to the observed
survival data. The value of 2 log likelihood (-2LL) was reported
for each model: lowers values giving better fit. Multivariate Cox
regression was also used to evaluate the association of PS score
(patient- or oncologist-assessed) with survival (for NSCLC and
SCLC), adjusting for sex and stage of disease (in NSCLC only). All
three variables were entered into the model as categorical
variables. The significance of PS score was assessed by the
likelihood ratio test on removal from the saturated model. The
2LL was also reported for these adjusted models.
RESULTS
In total, 10 oncologists took part in this study, consisting of two
consultants and eight specialist registrars. The majority of patients
were male (71%); the median age was 70 years (range 34– 88
years). All patients had a diagnosis of a malignancy, 81 with
NSCLC, 17 with SCLC and three who were subsequently found to
have secondary lung metastases from a non-lung primary. These
The ECOG PS score used in this study 
ECOG/WHO score 
0  Fully active, able to carry on all predisease performance 
 without restriction 
1  Restricted in physically strenuous activity, but ambulatory and
 able to carry out work of a light and sedentary nature (e.g. 
 light house work, office work) 
2 Ambulatory and capable of all self-care but unable to carry 
 out any work activities.  Up and about more than 50% of 
 waking hours. 
3  Capable of only limited self-care, confined to bed or chair 
 more than 50% of waking hours 
4 Completely disabled.  Cannot carry on any self-care.  Totally
 confined to bed or chair. 
5 Dead 
(PS score 5 was omitted from the trial questionnaire).
Figure 1 The ECOG PS score used in this study.
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three patients were excluded from the subsequent survival
analysis, so that of the remaining 98 patients with a primary
diagnosis of lung cancer, the median (IQR) survival time was 7.7
months (3.7,17) and at study completion, 20 patients (20%) were
still alive.
SCLC
Patients with SCLC were staged as limited or extensive disease
(Table 1). The majority (65%) of the 17 patients in this study with
SCLC had limited disease on diagnosis. Overall, their median
(IQR) survival from trial entry was 6.5 (2.2,12) months. As the
number of patients with SCLC in this study was small, stage-by-
stage analysis was not performed on them.
NSCLC
Of 81 patients with NSCLC, 72% had stage III or IV disease on
diagnosis (Table 1). The overall actuarial survival (95% CI) at 1
year from trial entry was 35% (25, 46). The 1-year survival rates by
stage were 64% (43, 85), 33% (18, 48), 11% (0, 24) for stages I or II,
III and IV, respectively (Figure 2).
Correlation of PS with survival
Performance status, whether assessed by oncologist or patient, was
significantly associated with survival in the 98 patients with
primary lung cancer (Pp0.001). (Tables 2 and 3, Figures 3 and 4).
Multivariate Cox’s regression showed that PS score was signifi-
cantly associated with survival in these patients, after adjustment
for sex (NSCLC and SCLC) and stage (NSCLC) (patient score
P¼ 0.005; doctor score P¼ 0.007).
Doctor –patient agreement
The patient- and oncologist-assessed PS scores are given in Table 4.
Patient and oncologist agreed in 51 (50%) of the cases. The
weighted k (95% CI) was 0.45 (0.33, 0.59) indicating moderate
agreement; they were generally similar in their PS assessment, but
patients were marginally less optimistic than their oncologists. In
cases where they disagreed, the PS scores were evenly spread with
46% of patients giving higher (optimistic) and 54% giving lower
(pessimistic) PS scores than their oncologists. There were only six
cases when PS scores differed by more than one point (see Table 5).
In the 12 cases where the patient scored themselves as PS 2, 11
(92%) patients were scored more optimistically by their oncologist
(i.e. given a score of 1 instead of 2). Although one patient did score
himself as PS 4, we would not expect patients of low PS in this
study as they were recruited as outpatients, and required mobility
to attend.
Sex difference and disease stage in PS assessment
There was no significant difference in the patient-assessed PS
scores when comparing males with females (P¼ 0.37), with
weighted k scores of 0.4 (0.24,0.55) and 0.57 (0.32, 0.81) for males
and females, respectively. However, on average, oncologists gave
lower scores to females more often than males (P¼ 0.04; margin-
ally significant).
Stage of disease (NSCLC only) was not associated with PS score,
whether assessed by patient or oncologist (both P¼ 0.18). The
distribution of patient – oncologist scores is given by stage of
disease in Table 4.
‘Accuracy’ of PS
To calculate which PS score (patient- or oncologist-assessed) was
the better fit to the observed survival data, a Cox regression model
was run with each score separately. For the univariate models the
values of 2LL were 615.1 and 612.7 for patient and oncologist,
Table 1 Disease type and stage of 98 patients with primary lung cancer in this study
Diagnosis Disease stage
Non-small-cell lung cancer 81 Ia 5 (6%) Ib 13 (16%) IIa 2 (3%) IIb 2 (3%) IIIa 14 (17%) IIIb 25 (31%) IV 19 (23%) u/k 1 (1%)
Small-cell lung cancer 17 Limited stage 11 (65%) Extensive stage 6 (35%)
u/k¼ unknown.
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Figure 2 Kaplan–Meier graph showing cumulative survival of 81 study
patients with a diagnosis of NSCLC according to the pathological stage of
their disease at diagnosis. Survival taken from date of trial entry until death
or completion of study (if alive).
Table 2 Survival by performance status (NSCLC and SCLC) assessed by
(a) patienta and (b) oncologistb
Score
Median survival
(months)
Cumulative survival
(95% CI) at 1 year
(a) Patient
0 12.9 52% (31, 73)
1 11.3 40% (25, 55)
2 6.5 17% (2, 33)
3–4 2.2 14% (0, 32)
(b) Doctor
0 18.9 67% (44, 88)
1 8.2 41% (26, 57)
2 6.5 17% (2, 35)
3–4 2.1 17% (0, 38)
In both cases, performance status correlated with survival (Pp0.001). This is
represented graphically in Figures 3 and 4. NSCLC¼ non-small-cell lung cancer;
SCLC¼ small-cell lung cancer; CI¼ confidence interval. aLog rank test P¼ 0.001.
bLog rank test Po0.001.
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respectively. Their corresponding values in the adjusted models
were 446.9 and 447.6. Both sets of figures indicated that scores fit
the observed data to a similar extent.
DISCUSSION
Correlation of PS with survival
Both patient- and oncologist-assessed scores correlated with
survival duration (Figures 3 and 4) confirming the findings of
other studies (Mor et al, 1984) that have validated PS as a reliable
prognostic marker in patients with cancer. Even allowing for sex
and stage of disease, patient- and oncologist-allocated PS scores
were independently associated with survival.
Doctor –patient agreement
We demonstrated moderate agreement between patients and
oncologists in their assessments of patients’ PS (weighted k
0.45). There was an even spread of PS scores, with patients and
oncologists rarely disagreeing by more than one PS point. This is
in contrast to the study by Ando et al (2001), which, although
demonstrating a higher incidence of agreements between oncol-
ogist and patient (k score 0.53), had wider disparity of scores in
those that did not agree. This occurred particularly in female
patients, who scored themselves more pessimistically than their
male counterparts. In our study, although there was no statistical
Table 3 Differences in oncologist- and patient-assessed performance
status (PS) scores in relation to disease stage, type and sex of patient
Doctor-assessed PS score compared
to patient assessed PS score
Group/subgroup (n)
Under-rated
(DoP) n (%)
Agree
(D¼P) n (%)
Over-rated
(D4P) n (%)
All patients (101) 27 (27) 51 (50) 23 (23)
Females (29) 3 (10) 16 (55) 10 (35)
Males (72) 24 (33) 35 (49) 13 (18)
NSCLC
Stage unknown (1) 1 (100) – –
Stage I (18) 5 (28) 9 (50) 4 (22)
Stage II (4) 1 (25) 3 (75) –
Stage III (39) 11 (28) 19 (49) 9 (23)
Stage IV (19) 6 (32) 6 (32) 7 (36)
SCLC
Limited (11) 1 (9) 8 (73) 2 (18)
Extensive (6) 1 (17) 4 (66) 1 (17)
Stage of NSCLC was not associated with PS score, whether assessed by patient or
oncologist (P¼ 0.18). Although there was no statistical difference in PS scores
between males and females (P¼ 0.37), oncologists generally gave lower PS scores to
female patients (P¼ 0.04, marginally significant). D¼ doctor-assessed PS score;
P¼ patient-assessed PS score; NSCLC¼ non-small-cell lung cancer; SCLC¼ small-
cell lung cancer.
PS=0
PS=1
PS=2
PS=3 or 4
Survival by patient-rated PS score
Months
Cu
m
ul
at
ive
 s
ur
viv
al
 (%
)
0 5 10 15 20 25
0
20
40
60
80
100
Figure 3 Kaplan–Meier graph showing cumulative survival in patients
with NSCLC according to their patient-assessed PS scores (data: Table 2).
Survival correlated with PS, P¼ 0.001.
Survival by doctor-rated PS score
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Figure 4 Kaplan–Meier graph showing cumulative survival in patients
with NSCLC according to their oncologist-assessed performance status
scores (data: Table 2). Survival correlated with PS, Po0.001.
Table 4 Performance status (PS) scores (NSCLC and SCLC) as assessed
by patient (vertical axis) and oncologist (horizontal axis)
ONCOLOGIST
Score 0 1 2 3 4
PATIENT 0 10 10 2 0 0
1 10 22 8 2 0
2 0 11 11 1 0
3 0 2 3 8 0
4 0 0 0 1 0
Numbers underlined are cases when oncologist and patient agreed over PS score.
Overall, weighted k score¼ 0.45 (0.33, 0.59) indicating moderate agreement
between patient- and oncologist-assessed scores.
Table 5 Characteristics of the six patients who differed in subjective and
objective performance status scores by 2 or more points
Patient Sex
Disease stage
(NSCLC)
Survival
(days)
Patient
assessed
score
Doctor-
assessed
score
1 Male III 69 1 3
2 Male III 175 0 2
3 Female IV 118 0 2
4 Female IV 432 1 3
5 Male IV 23 3 1
6 Male IV 211 3 1
Performance status score
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difference in subjective PS scoring between male and female
patients, our oncologists tended to score the female patients more
pessimistically than the males. The contrast in results between the
Ando study in Japan and ours could reflect different cultural
perceptions of illness or variations in study design: the Ando study
was carried out on sequential in-patients with NSCLC, whereas
ours was performed in the two-stop outpatient clinic with patients
who were awaiting confirmation of a primary lung cancer
diagnosis.
The even spread of PS scores in our results was belied by the k
score that showed only moderate agreement between oncologist
and patient. The greatest area of disagreement appeared to be over
the assignation of PS score 2 with oncologists often choosing
PS¼ 0 or 1 instead.
Disease stage and PS
Here, 10 oncology registrars or consultants were involved, which
may have caused bias, as they were of different sex, age and clinical
experience. However, we designed this trial to reflect current
practice in the lung cancer clinic and to reduce potential
assessment-bias from an individual doctor in PS allocation.
Participating oncologists had the benefit of reading patients’ notes
and viewing staging test results before allocating a PS score and
this could have influenced their assessments. In a trial of this
design, it would be difficult to demonstrate whether or not this
occurred. However, we showed no statistical correlation between
oncologist-assigned PS and stage of disease (P¼ 0.18), indicating
that they were not using disease stage to guide their assessment. If
this had been the case, patients with more extensive disease would
have been assigned lower PS scores.
Also, we compared the survival of patients with NSCLC in this
study to that of 170 similar patients seen in the two-stop clinic in
1998. This was to show that patients in our study were typical of
those seen in the two-stop clinic, and were managed according to
usual clinical practice. In the 1998 group, 1-year survival was 35%
(28%, 42%). There was no significant difference (P¼ 0.77) in
overall survival, adjusted for stage, between the 1998 patients and
those in our study (Figure 5).
‘Accuracy’ of PS assessment
So which PS scores showed greatest prognostic accuracy, those
decided by the patients or by their oncologists? Comparing the PS-
related survival of patients in the oncologist-assessed, and then the
patient-assessed groups to that recorded in other studies would
address this. However, despite the fact that PS scores are known to
correlate to survival, few studies have quantified the expected
survival for each PS score in NSCLC. Survival differs for every type
of cancer, and in the few studies where it is quantified; the PS
scores have always been doctor-assessed (Buccheri et al, 1996).
However, using the univariate Cox’s regression model, we showed
that, within the limits of this study, patient- and oncologist-
assessed PS score reflected survival to a similar degree.
An important criticism of this type of study is that bias may be
introduced if treatment is assigned to patients on the basis of the
oncologist-assessed PS score. Thus, if an oncologist gave a fit
patient a PS of 3, the patient would then receive supportive care
rather than active treatment (with surgery, chemotherapy or
radiotherapy). If active treatment were to have a large impact on
survival, then a patient receiving supportive care would have a
shorter survival duration than if he had received active treatment.
The initial low PS score given by the oncologist would thus be self-
fulfilling. This bias is not obviated by comparing survival in each
PS score to that of patients with similar PS scores in other studies,
as PS is doctor-assessed in those studies too. However, NSCLC is
notoriously poorly responsive to active treatment, so theoretically
bias should be minimal when compared to patients with more
treatable cancers.
Although patients and oncologists rarely differed by more than
one PS point, a few patients gave surprisingly poor scores, even
though they appeared to be in good health. The reason behind this
variation in scores was not explored in this study, but could be
explained by physical or psychological comorbidity that was
overlooked by the oncologists. Hopwood and Stephens (2000)
demonstrated that 33% patients with lung cancer had self-reported
depressive illness, which can negatively impact on their response
to treatment (Stommel et al, 2002) and was frequently
undiagnosed by their oncologists (Ford et al, 1994). If patients
are routinely asked to assess their own PS, and this is used as a
basis for discussion during clinic, concerns (such as comorbidity)
may be raised and addressed. Six patients and oncologists
disagreed over the PS score by more than 2 points and are listed
in Table 5. The numbers are too small from which to draw any
statistical conclusions, but among these patients neither the
oncologists nor the patients themselves were generally more
optimistic in their PS assessment. All six patients had stage III or
IV NSCLC at the time of assessment and died before the study was
completed.
In this study, patients had not received a confirmed diagnosis of
cancer, and it is difficult to estimate how much this contributed to
their PS assessment. Ascribing treatment purely on the basis of
patient PS assessment could perhaps introduce its own problems
with bias. Those with unrealistically optimistic expectations of a
trial outcome may overestimate their own PS scores in order to
meet trial entry criteria. Equally, those wishing to avoid entering a
certain clinical trial may be unduly pessimistic about their PS.
However, oncologists could be just as likely to introduce bias,
especially with patients on the borderline between PS 1 and 2, the
cut off point for many of the combination chemotherapy trials.
In conclusion, PS is a simple and useful tool, either used alone
or in the context of a multivariable prognostic test. This study
showed that, for patients with NSCLC, PS correlated with overall
survival; whether assessed by the patients themselves or their
treating oncologists. We showed that patients are reliable assessors
of their own PS, although it is not known how much this would
differ if they had previously been made aware of their diagnosis.
Involving the patient in PS score allocation may not only highlight
their concerns and comorbidity, but may also reduce oncologist
interobserver variation and sex bias. It would be interesting to
extend this trial to include more SCLC patients as well as involving
patients with other cancer types.
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Figure 5 Overall survival of 170 (nonstudy) patients with NSCLC
enrolled in the two-stop clinic in 1998 compared with survival of 81 (study)
patients with NSCLC. There was no statistical difference in survival
between them. P¼ 0.83.
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